<p>BioLife Solutions, Inc.（納斯達克代碼：BLFS - 獲取免費報告）執行副總裁 Aby J. Mathew 於 5 月 28 日（星期三）出售了 521 股 BioLife Solutions 股票。該股票以平均價格 22.46 美元出售，總交易額為 11,701.66 美元。交易後，該執行副總裁現在直接持有 308,486 股公司股票，價值 6,928,595.56 美元。此次交易使其持股減少了 0.17%。該交易已在與證券交易委員會的法律文件中披露，具體內容可通過此鏈接查看。</p>
<p>獲取 <strong>BioLife Solutions</strong> 警報：</p>
<h2>BioLife Solutions 股價下跌 2.2%</h2>
<ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
<p>BLFS 股票在週五下跌 0.49 美元，達到 21.83 美元。該公司的股票交易量為 786,262 股，而其平均交易量為 389,140 股。該公司的債務與股本比率為 0.03，速動比率為 1.78，流動比率為 2.78。該公司的市值為 10.4 億美元，市盈率為-20.59，貝塔值為 2.01。該公司 50 日簡單移動平均線為 22.94 美元，200 日簡單移動平均線為 25.09 美元。BioLife Solutions, Inc.的 12 個月低點為 18.70 美元，12 個月高點為 29.55 美元。</p>
<p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）最近於 5 月 8 日（星期四）發佈了季度財報。該醫療設備提供商報告本季度每股收益為 0.04 美元，超出分析師一致預期的-0.03 美元，超出幅度為 0.07 美元。該公司本季度的收入為 2394 萬美元，而分析師預期為 2222 萬美元。BioLife Solutions 的股本回報率為-6.61%，淨利潤率為-38.98%。作為一個整體，研究分析師預測 BioLife Solutions, Inc.在本年度將發佈-0.3 的每股收益。</p>
<h2>BioLife Solutions 的機構交易</h2>
<ul>
<li>3 只小型醫療股今日市場動向</li>
</ul>
<p>幾家對沖基金和其他機構投資者最近買入和賣出了該股票的股份。T. Rowe Price Investment Management Inc.在第一季度收購了 BioLife Solutions 的新股份，價值約 30,789,000 美元。Raymond James Financial Inc.在第四季度收購了 BioLife Solutions 的新頭寸，價值約 20,664,000 美元。馬薩諸塞金融服務公司在第四季度收購了 BioLife Solutions 的新股份，價值約 19,805,000 美元。加拿大皇家銀行在第一季度將其在 BioLife Solutions 的股份增加了 762.8%。加拿大皇家銀行現在持有 698,251 股該醫療設備提供商的股票，價值 15,948,000 美元，此前在上個季度又收購了 617,320 股。最後，Point72 Asset Management L.P.在第四季度購買了 BioLife Solutions 的新頭寸，價值約 11,113,000 美元。93.24% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師觀點</h2>
<p>BLFS 已成為幾份研究報告的主題。HC Wainwright 在 5 月 13 日（星期二）的報告中重申了對 BioLife Solutions 的 “買入” 評級，並給出了 30.00 美元的目標價格。Wall Street Zen 在 5 月 21 日（星期三）的報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了賣出評級，而六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為 31.17 美元。</p>
<p><strong>閲讀我們關於 BioLife Solutions 的最新報告</strong></p>
<h2>BioLife Solutions 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>BioLife Solutions, Inc.開發、製造和銷售生物生產工具和服務，服務於美國、歐洲、中東、非洲及國際的細胞和基因治療（CGT）行業。該公司的產品用於生物基療法的基礎和應用研究以及商業製造。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票比 BioLife Solutions 更好</li>
<li>投資石油股票的方式和原因</li>
<li>耐克在亞馬遜的擴張可能預示着 2025 年的轉機</li>
<li>3 只引領迷因股復興的股票</li>
<li>英特爾的轉機可能是無人關注的最佳選擇</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只將從金頂中獲利的防禦性股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 BioLife Solutions 嗎？</h2>
<p>在你考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 BioLife Solutions 並不在名單上。</p>
<p>雖然 BioLife Solutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BLFS

<p>BioLife Solutions, Inc.（納斯達克代碼：BLFS）執行副總裁 Aby J. Mathew 以每股 22.46 美元的價格出售了 521 股，總計 11,701.66 美元。出售後，他持有 308,486 股，價值約 693 萬美元，持股比例減少了 0.17%。該股票最近下跌 2.2%，報 21.83 美元。BioLife 在上個季度報告的每股收益為 0.04 美元，超出預期，收入為 2394 萬美元。分析師對該股票的共識評級為 “適度買入”，平均目標價為 31.17 美元。機構投資者持有該股票的 93.24%</p>

<p>BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 521 shares of BioLife Solutions stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $22.46, for a total transaction of $11,701.66. Following the transaction, the executive vice president now directly owns 308,486 shares in the company, valued at $6,928,595.56. The trade was a 0.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.（納斯達克代碼：BLFS - 獲取免費報告）執行副總裁 Aby J. Mathew 於 5 月 28 日（星期三）出售了 521 股 BioLife Solutions 股票。該股票以平均價格 22.46 美元出售，總交易額為 11,701.66 美元。交易後，該執行副總裁現在直接持有 308,486 股公司股票，價值 6,928,595.56 美元。此次交易使其持股減少了 0.17%。該交易已在與證券交易委員會的法律文件中披露，具體內容可通過此鏈接查看。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>BioLife Solutions</strong> 警報：</p>
</div><h2>BioLife Solutions Trading Down 2.2%</h2>
<div class="lb-trans"><h2>BioLife Solutions 股價下跌 2.2%</h2>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
</div><p>BLFS stock traded down $0.49 on Friday, reaching $21.83. The company's stock had a trading volume of 786,262 shares, compared to its average volume of 389,140. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.04 billion, a PE ratio of -20.59 and a beta of 2.01. The business has a fifty day simple moving average of $22.94 and a two-hundred day simple moving average of $25.09. BioLife Solutions, Inc. has a 12-month low of $18.70 and a 12-month high of $29.55.</p>
<div class="lb-trans"><p>BLFS 股票在週五下跌 0.49 美元，達到 21.83 美元。該公司的股票交易量為 786,262 股，而其平均交易量為 389,140 股。該公司的債務與股本比率為 0.03，速動比率為 1.78，流動比率為 2.78。該公司的市值為 10.4 億美元，市盈率為-20.59，貝塔值為 2.01。該公司 50 日簡單移動平均線為 22.94 美元，200 日簡單移動平均線為 25.09 美元。BioLife Solutions, Inc.的 12 個月低點為 18.70 美元，12 個月高點為 29.55 美元。</p>
</div><p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. The firm had revenue of $23.94 million for the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. As a group, research analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）最近於 5 月 8 日（星期四）發佈了季度財報。該醫療設備提供商報告本季度每股收益為 0.04 美元，超出分析師一致預期的-0.03 美元，超出幅度為 0.07 美元。該公司本季度的收入為 2394 萬美元，而分析師預期為 2222 萬美元。BioLife Solutions 的股本回報率為-6.61%，淨利潤率為-38.98%。作為一個整體，研究分析師預測 BioLife Solutions, Inc.在本年度將發佈-0.3 的每股收益。</p>
</div><h2>Institutional Trading of BioLife Solutions</h2>
<div class="lb-trans"><h2>BioLife Solutions 的機構交易</h2>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型醫療股今日市場動向</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. acquired a new stake in shares of BioLife Solutions in the first quarter worth approximately $30,789,000. Raymond James Financial Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter worth about $20,664,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at about $19,805,000. Royal Bank of Canada raised its stake in BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after acquiring an additional 617,320 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of BioLife Solutions during the 4th quarter worth approximately $11,113,000. 93.24% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買入和賣出了該股票的股份。T. Rowe Price Investment Management Inc.在第一季度收購了 BioLife Solutions 的新股份，價值約 30,789,000 美元。Raymond James Financial Inc.在第四季度收購了 BioLife Solutions 的新頭寸，價值約 20,664,000 美元。馬薩諸塞金融服務公司在第四季度收購了 BioLife Solutions 的新股份，價值約 19,805,000 美元。加拿大皇家銀行在第一季度將其在 BioLife Solutions 的股份增加了 762.8%。加拿大皇家銀行現在持有 698,251 股該醫療設備提供商的股票，價值 15,948,000 美元，此前在上個季度又收購了 617,320 股。最後，Point72 Asset Management L.P.在第四季度購買了 BioLife Solutions 的新頭寸，價值約 11,113,000 美元。93.24% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>BLFS has been the topic of several research reports. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Tuesday, May 13th. Wall Street Zen lowered shares of BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $31.17.</p>
<div class="lb-trans"><p>BLFS 已成為幾份研究報告的主題。HC Wainwright 在 5 月 13 日（星期二）的報告中重申了對 BioLife Solutions 的 “買入” 評級，並給出了 30.00 美元的目標價格。Wall Street Zen 在 5 月 21 日（星期三）的報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。一位研究分析師對該股票給予了賣出評級，而六位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，平均目標價格為 31.17 美元。</p>
</div><p><strong>Read Our Latest Report on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 BioLife Solutions 的最新報告</strong></p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.開發、製造和銷售生物生產工具和服務，服務於美國、歐洲、中東、非洲及國際的細胞和基因治療（CGT）行業。該公司的產品用於生物基療法的基礎和應用研究以及商業製造。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Nike’s Amazon Expansion Could Signal a Turnaround in 2025</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 BioLife Solutions 更好</li>
<li>投資石油股票的方式和原因</li>
<li>耐克在亞馬遜的擴張可能預示着 2025 年的轉機</li>
<li>3 只引領迷因股復興的股票</li>
<li>英特爾的轉機可能是無人關注的最佳選擇</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>3 只將從金頂中獲利的防禦性股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 BioLife Solutions 嗎？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 BioLife Solutions 並不在名單上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioLife Solutions 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

BioLife Solutions, Inc.（NASDAQ: BLFS）的執行副總裁出售了價值 11,701.66 美元的股票